Valuation: Veru Inc.

Market Cap 35.95M 31.25M 29.09M 26.71M 50.44M 3.43B 51.22M 343M 135M 1.71B 135M 132M 5.73B P/E 2026 *
-2.21x
P/E 2027 * -2.27x
Enterprise Value 35.95M 31.25M 29.09M 26.71M 50.44M 3.43B 51.22M 343M 135M 1.71B 135M 132M 5.73B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.01%
Yield 2026 *
-
Yield 2027 * -
1 day+0.90%
1 week-0.44%
1 month-29.11%
3 months-0.88%
6 months-11.46%
Current year+4.67%
1 week 2.16
Extreme 2.16
2.4
1 month 2.16
Extreme 2.16
2.99
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 2016-10-30
Director of Finance/CFO 67 2012-12-31
Chief Tech/Sci/R&D Officer 64 2018-03-31
Director TitleAgeSince
Chairman 65 2018-02-28
Director/Board Member 68 2016-09-30
Director/Board Member 68 2018-02-28
Date Insider Type Main position Quantity % Market Cap.
12/5/25 Free

Chief Technology Officer

27,000 0.1681%
12/5/25 Free

Director

3,000 0.0187%
12/5/25 Free

Chief Executive Officer

100,000 0.6227%
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%-0.44%-54.61%-81.33% 35.95M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -0.02%-3.80%+26.82%+131.20% 23.39B
Weighted average by Cap. +0.23%-2.96%+30.78%+116.81%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.82M -20.31M -18.65M -35.21M -2.4B -35.76M -239M -93.95M -1.19B -94.27M -92.19M -4B -37.1M -32.25M -30.02M -27.56M -52.05M -3.54B -52.85M -354M -139M -1.76B -139M -136M -5.91B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
26-07-31 US$2.240 +0.90% 153,698
26-07-30 US$2.220 +0.45% 133,724
26-07-29 US$2.210 -0.90% 196,701
26-07-28 US$2.230 -2.19% 197,984
26-07-27 US$2.280 +1.33% 476,054
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.240USD
Average target price
24.50USD
Spread / Average Target
+993.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock